Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Treatment Studies for People with ER-Positive, HER2-Negative Advanced or Metastatic Breast Cancer (TACTIVE-U)
Glossary on
off
Printer Friendly Page Treatment Studies for People with ER-Positive, HER2-Negative Advanced or Metastatic Breast Cancer (TACTIVE-U)

Treatment Studies for People with ER-Positive, HER2-Negative Advanced or Metastatic Breast Cancer (TACTIVE-U)


Treatment for ER-positive, HER2-negative metastatic breast cancer

Studies for People with ER-Positive, HER2-Negative Advanced or Metastatic Breast Cancer (TACTIVE-U)

About the Study

NOTE - This study is no longer recruiting patients. 

 

Researchers at Pfizer and Arvinas are conducting the TACTIVE-U studies for people with ER-positive, advanced or breast cancer who have received at least one prior round of treatment and no more than two prior rounds of treatments for advanced or disease. One of these rounds of treatment must have included a CDK4/6 inhibitor (e.g., Kisqali, Verzenio, Ibrance).

 

This Study is Open To:

NOTE - This study is no longer recruiting patients. 

This Study is Not Open To:

NOTE - This study is no longer recruiting patients.